Casdin Capital 13F holdings, Q2 2021
Holdings as of June 30, 2021 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 54 US equity positions worth $3.9bn in its Q2 2021 13F filing. The largest position was INVITAE CORP at 10.4% of the reported book, followed by BLFS and FATE. Against the Q1 2021 filing, it opened 10 new positions, added to 8 and reduced 3 among the top 50 holdings.
What did Casdin Capital own in Q2 2021? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2021 |
|---|---|---|---|---|---|---|---|
| 1 | INVITAE CORP | 10.4% | $411.6m | 12,203,669 | 0% | held | |
| 2 | BLFS BIOLIFE SOLUTIONS INC | Healthcare | 8.4% | $331.2m | 7,440,107 | 0% | held |
| 3 | FATE FATE THERAPEUTICS INC | Healthcare | 7.5% | $295.1m | 3,400,000 | 0% | held |
| 4 | EXK EXACT SCIENCES CORP | Basic Materials | 7.4% | $293.4m | 2,360,186 | 0% | held |
| 5 | VERVE THERAPEUTICS INC | 4.6% | $183.1m | 3,038,167 | – | new | |
| 6 | PACB PACIFIC BIOSCIENCES CALIF IN | Healthcare | 4.4% | $174.8m | 5,000,000 | 0% | held |
| 7 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 4.3% | $169.5m | 1,000,000 | 14% | added |
| 8 | 2655787D BLUEPRINT MEDICINES CORP | 3.5% | $136.3m | 1,550,000 | 0% | held | |
| 9 | TWST TWIST BIOSCIENCE CORP | Healthcare | 3.4% | $133.2m | 1,000,000 | 0% | held |
| 10 | DNLI DENALI THERAPEUTICS INC | Healthcare | 3.2% | $126.3m | 1,610,000 | 0% | held |
| 11 | RLAY RELAY THERAPEUTICS INC | Healthcare | 3.1% | $123.5m | 3,375,058 | 0% | held |
| 12 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 3.0% | $119.3m | 2,165,000 | 0% | held |
| 13 | CDNA CAREDX INC | Healthcare | 2.8% | $109.2m | 1,193,335 | 0% | held |
| 14 | BEAM BEAM THERAPEUTICS INC | Healthcare | 2.7% | $105.4m | 818,820 | 0% | held |
| 15 | CDXS CODEXIS INC | Healthcare | 2.5% | $98.1m | 4,330,000 | 0% | held |
| 16 | IPSC CENTURY THERAPEUTICS INC | Healthcare | 2.4% | $94.1m | 3,206,380 | – | new |
| 17 | SINGULAR GENOMICS SYSTEMS IN | 1.9% | $74.0m | 2,692,870 | – | new | |
| 18 | RVMD REVOLUTION MEDICINES INC | Healthcare | 1.9% | $73.2m | 2,305,000 | 25% | added |
| 19 | DERMTECH INC | 1.8% | $72.5m | 1,745,000 | 0% | held | |
| 20 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 1.7% | $68.8m | 885,000 | 61% | added |
| 21 | ADPT ADAPTIVE BIOTECHNOLOGIES COR | Healthcare | 1.5% | $58.8m | 1,440,000 | 25% | added |
| 22 | ONC BEIGENE LTD | Healthcare | 1.3% | $51.5m | 150,000 | 0% | held |
| 23 | AMYRIS INC | 1.2% | $49.1m | 3,000,000 | – | new | |
| 24 | GLOBAL BLOOD THERAPEUTICS IN | 1.2% | $45.9m | 1,310,000 | 46% | added | |
| 25 | CNST CONSTELLATION PHARMCETICLS I | 1.2% | $45.3m | 1,341,000 | -26% | reduced | |
| 26 | GENERATION BIO CO | 1.1% | $43.3m | 1,611,214 | 0% | held | |
| 27 | CRSP CRISPR THERAPEUTICS AG | Healthcare | 1.1% | $43.1m | 266,430 | 0% | held |
| 28 | ALEC ALECTOR INC | Healthcare | 0.9% | $34.4m | 1,650,000 | 0% | held |
| 29 | ZLAB ZAI LAB LTD | Healthcare | 0.9% | $33.6m | 190,000 | 0% | held |
| 30 | MAGENTA THERAPEUTICS INC | 0.8% | $32.7m | 3,346,034 | 0% | held | |
| 31 | 23ANDME HOLDING CO | 0.8% | $32.0m | 2,741,457 | – | new | |
| 32 | ALLO ALLOGENE THERAPEUTICS INC | Healthcare | 0.8% | $31.9m | 1,225,000 | -6% | reduced |
| 33 | 4D MOLECULAR THERAPEUTICS IN | 0.7% | $26.9m | 1,115,555 | 12% | added | |
| 34 | NEO NEOGENOMICS INC | Healthcare | 0.6% | $22.1m | 488,889 | – | new |
| 35 | GLUE MONTE ROSA THERAPEUTICS INC | 0.6% | $21.8m | 960,883 | – | new | |
| 36 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 0.5% | $20.6m | 1,200,000 | 20% | added |
| 37 | RXRX RECURSION PHARMACEUTICALS IN | Healthcare | 0.5% | $20.0m | 548,156 | – | new |
| 38 | MASS 908 DEVICES INC | 0.4% | $15.8m | 406,502 | 0% | held | |
| 39 | ORCHARD THERAPEUTICS PLC | 0.4% | $14.1m | 3,215,434 | 0% | held | |
| 40 | KRONOS BIO INC | 0.4% | $14.0m | 583,436 | 0% | held | |
| 41 | FULC FULCRUM THERAPEUTICS INC | Healthcare | 0.3% | $12.1m | 1,154,476 | -7% | reduced |
| 42 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 0.3% | $10.6m | 601,515 | 0% | held |
| 43 | DECIBEL THERAPEUTICS INC | 0.3% | $10.1m | 1,171,421 | 2% | added | |
| 44 | CLOV CLOVER HEALTH INVESTMENTS CO | Healthcare | 0.2% | $9.7m | 726,511 | 0% | held |
| 45 | BERKELEY LTS INC | 0.2% | $9.0m | 200,000 | 0% | held | |
| 46 | TKNO ALPHA TEKNOVA INC | 0.2% | $7.1m | 300,000 | – | new | |
| 47 | SGMOQ SANGAMO THERAPEUTICS INC | Healthcare | 0.2% | $6.6m | 550,000 | 0% | held |
| 48 | TURNING POINT THERAPEUTICS I | 0.1% | $5.9m | 75,000 | 0% | held | |
| 49 | NAUT NAUTILUS BIOTECHNOLOGY INC | 0.1% | $5.0m | 500,000 | – | new | |
| 50 | SEER SEER INC | 0.1% | $4.9m | 150,000 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.